INTRODUCTION
The gut epithelium represents the largest barrier in the body, and its continuous cross-talk with gut microbiota is critical for health. 1 Mucosal homeostasis depends on the interplay between epithelia and the immune system. 2 These finely balanced pro-inflammatory and tolerogenic mechanisms are vital for preventing pathogenic infections and fine tuning the microbiome. 3 T-and B cells are viewed as the main immunological players, although innate lymphoid cells (ILCs) have been recently shown to have a prominent role. 4 The cytokine interleukin-22 (IL)-22, produced by type 3 ILCs (ILC3) and/or T-cells, is crucial to this process, regulating epithelial proliferation and tissue regeneration, as well as the production of antimicrobial peptides. 5 Equally important for protection against infections is IL-17, a pro-inflammatory cytokine that can also be produced by ILC3 and CD4 T-cells. Of note, maintenance of gut homeostasis requires a balance between IL-17 production and suppressive mechanisms mainly driven by regulatory T-cells (Tregs). 6, 7 Disruption of mucosal integrity is considered a main determinant of gut and systemic diseases, such as HIV/AIDS. 8 HIV-1 and Simian Immunodeficiency Virus (SIV) have been shown to impact on the bowel mucosa in acute infection, leading to a depletion of CD4 T-cells from the lamina propria that persists throughout the chronic phase, with antiretroviral therapy (ART) failing to consistently recover this deficit. 9, 10 Moreover, this lack of immunological reconstitution at the mucosal level is linked to persistent inflammation and comorbidities in long-term-treated HIV-1-infected individuals. 11 The loss of mucosal CD4 T-cells able to produce IL-17 (Th17) and/or IL-22 (Th22) is particularly marked, and is paralleled by a relative expansion of Foxp3-expressing Tregs. 12 Although, CD4 T-cell loss has been attributed to the direct cytopathic effects of the virus, other mechanisms are also likely to be involved such as alterations in T-cell traffic and mucosal recruitment, as well as collagen deposition leading to architectural alterations. 13, 14 Furthermore, recent reports emphasize the concomitant loss of ILC3, which are not direct targets of HIV/SIV infection, 15 as well as epithelial leakage, leading to gut microenvironment disruption. 16 In agreement with an important role for ILC3, we have recently shown that a preserved ILC3 compartment was associated with mucosal integrity in long-term-treated HIV-1 individuals with persistent CD4 T-cell depletion. 17 The strategies utilized by the gut to cope with persistent viral infection remain undefined. In order to address this, we investigated gut homeostasis in the context of chronic HIV-2 infection, which is characterized by reduced mortality in the absence of ART. 18 HIV-2-infected individuals feature a progressive CD4 T-cell depletion that directly correlates with markers of immune activation and systemic inflammation as observed in HIV-1 infection, but with a much slower rate of progression to AIDS. 19, 20 Importantly, HIV-2 targets the same cell populations as HIV-1, and is able to establish a disseminated infection with evidence of persistent ongoing viral replication despite the low to undetectable viremia observed even in the absence of ART. 21, 22 The mechanisms underlying this relatively benign course are incompletely understood, but are unlikely to result from intrinsic viral properties, 23 and may be in part due to the host-specific immune responses. 24 As yet, no direct studies of gut mucosa in HIV-2-infected individuals have been reported. A previous study conducted in an African setting showed increased plasma lipopolysaccharide levels, suggesting that gut leakage and microbial translocation occurs in HIV-2 infection. 25 We have compared Europeanresident HIV-2-and HIV-1-infected individuals and found that, in contrast to HIV-1, there was no significant increase in lipopolysaccharide levels in HIV-2 infection despite the upregulation of markers of T-cell and monocyte activation in both infections. Therefore, we reasoned that the investigation of gut mucosa in HIV-2 infection could reveal mechanisms able to counteract the impact of persistent injury, such as that caused by HIV.
We found evidence of HIV-2 replication in both sigmoid and ileal biopsies from HIV-2-infected individuals irrespective of ART. Notwithstanding this, absolute numbers of CD4 T-cells, including Th17/Th22 and FOXP3 þ Tregs, as well as of ILC3, were preserved in the lamina propria. T-cell preservation was associated with increased expression of granulocyte-macrophage colony-stimulating factor (GM-CSF) that directly correlated with levels of chemokines involved in Th17 and Th22 recruitment, CCL20 and CCL28, respectively. Importantly, epithelial tight junctions were not disrupted and in vitro data confirmed the lack of impact of HIV-2 isolates on the expression of the tight junction protein zonula occludens (ZO-1). Overall, our data support a model in which the inability of HIV-2 to perturb epithelial integrity allows for the development of mechanisms able to maintain mucosal homeostasis in the context of viral replication.
RESULTS

Evidence of HIV-2 replication in the gut mucosa
We first asked whether HIV-2 infects and replicates in the gut mucosa. Sigmoid and ileum biopsies were collected during routine colon cancer screening from 13 HIV-2-infected individuals, featuring undetectable viremia even in the absence of ART (Table 1) . HIV-2 patients featured a broad distribution of circulating CD4 T-cell counts. Of note, there were no significant differences between treated and untreated HIV-2-infected patients, except for lower levels of CD8 T-cells and monocyte activation markers in treated individuals ( Table 1) . In agreement with previous reports, 21, 27 ART was not associated with significant increase of circulating CD4 T-cell levels or changes in CD4 T-cell activation markers ( Table 1) . We quantified cell-associated HIV-2 DNA in sigmoid and ileum biopsies, and found that 8/11 ileum and 11/12 sigmoid biopsies assessed were positive, featuring comparable levels ( Figure 1a , P ¼ 0.27). Of note, cell-associated DNA levels were significantly higher in sigmoid than in peripheral blood mononuclear cells (PBMC) (P ¼ 0.04). We further confirmed HIV-2 mucosal replication via immunohistochemistry using a previously validated anti-HIV-2 Gag-specific antibody, 22 using one biopsy per patient. Cells positive for HIV-2 Gag protein were detected in both sigmoid and ileum biopsies irrespective of antiretroviral treatment (sigmoid: 2/6 untreated and 3/7 ART patients; ileum: 1/5 untreated and 3/7 ART patients, Figure 1b) .
Overall, our results reveal for the first time that HIV-2 infects and continuously replicates in the gut mucosa, despite the studied HIV-2-infected patients featuring undetectable viremia and irrespectively of ART.
CD4 T-cells are not depleted in the gut of HIV-2-infected patients
Next, we asked whether ongoing viral replication was associated with mucosal CD4 T-cell depletion in HIV-2-infected individuals, as observed in HIV-1 and SIV infections. 9 We found no differences between HIV-2-infected and seronegative individuals in terms of the number of lamina propria CD4 T-cells in ileum (Figure 2a , P ¼ 0.47) and sigmoid ( Figure 2b , P ¼ 0.27) biopsies, quantified by immunohistochemistry, or in the proportion of CD4 T-cells within total sigmoid lymphocytes, assessed in biopsy-derived cell suspensions by flow cytometry (Figure 2c , P ¼ 0.27).
In agreement with the presence of mucosal viral replication we found increased proportions of CD8 T-cells in sigmoid mucosa (Figure 2c Of note, untreated and treated HIV-2-infected individuals featured no differences in sigmoid CD4 cells/mm 2 We also found no association between sigmoid CD4 T-cell numbers and the frequency of HLA-DR þ CD38 þ cells within circulating CD4 and CD8 T-cell subsets (r ¼ À 0.39; P ¼ 0.21 and r ¼ À 0.08; P ¼ 0.80, respectively), or with the proportion of CD16 bright monocytes (r ¼ À 0.32; P ¼ 0.34). Thus, in HIV-2-infected individuals, the significant increase in activation markers within circulating CD4 and CD8 T-cells, as well as monocytes ( Table 1) , was not linked to depletion of mucosal CD4 T-cells.
In summary, gut mucosal CD4 T-cells were preserved during chronic HIV-2 infection despite the evidence of ongoing viral replication at this site.
Preserved mucosal Th17/Treg balance during HIV-2 infection
The functional characterization of the mucosal CD4 T-cell compartment revealed that IL-17-producing CD4 T-cells were preserved, with no difference in their frequency in cell suspensions generated from sigmoid biopsies of HIV-2 and seronegative individuals ( The balance between these two populations is considered particularly relevant for maintaining mucosal homeostasis. 28, 29 This was also unaltered in HIV-2 infection (IL-17 þ /FOXP3 þ cell counts in sigmoid: 1.99 (0.29-3.98, n ¼ 12) vs. 0.69 (0.27-1.98, n ¼ 14), P ¼ 0.14; and ileum 1.23 (0-4.62, n ¼ 11) vs. 2.48 (0.90-5.87, n ¼ 11), P ¼ 0.27; in HIV-2-infected and control individuals, respectively).
Overall, the lack of mucosal CD4 T-cell depletion is also accompanied by a preserved balance between Th17 and FOXP3 þ cells in HIV-2 infection.
IL-22-dependent mucosal homeostasis is preserved in HIV-2 infection
IL-22 is fundamental for maintaining gut homeostasis, as it facilitates a unique cross-talk between immune cells and epithelia, particularly in persistent inflammation. 5 We first assessed whether Th22 were preserved in HIV-2-infected individuals. The distribution within total CD4 T-cells of the subsets able to produce one, two, or the three cytokines (IL-17, IL-22, and IFNg), was similar in HIV-2-infected and healthy individuals ( Figure Regarding ILC3, defined here as cKit þ Nkp44 þ cells lacking lineage markers, 30 we found similar frequencies within total CD45 þ cells in both cohorts (Figure 4d , P ¼ 0.41). Additionally, as ILC3 constitute the major non-T-cell source of IL-22, 4 we quantified the frequency of IL-22-producing cells within a CD3 À gate and found no differences between HIV-2-infected and seronegatives individuals (6.1 (2.9-7.5)% vs. 2.6 (0.8-9.0)%, respectively; P ¼ 0.13). As ILC3 can also produce IL-17, 4 it is also worth noting that the frequency of IL-17-producing CD3 À cells was similar (2.5 (2.1-3.5) vs. 2.6 (0.8-9.0) in HIV-2-infected and seronegative individuals, respectively; P ¼ 0.14). Furthermore, we assessed the numbers of ILC3, defined as CD3 À RORg þ IL-22 þ cells, in sigmoid and ileum biopsy sections by immunofluorescence ( Figure 5b bottom, P ¼ 0.62; Figure 5c bottom, P ¼ 0.65, respectively), and found no inter-cohort differences.
In order to evaluate the functional implications of these findings, we quantified the expression levels of mucins and antimicrobial peptides regulated by IL-22 signaling. Bulk mucin production was evaluated by periodic acid Shiff-Alcien Blue staining, and found to be similar in sigmoid and ileum biopsies of seronegative and HIV-2-infected individuals (Figure 5e and f, respectively). Furthermore, we found no inter-cohort differences in mucin and antimicrobial peptide gene expression levels in either sigmoid or ileum (Figure 5e and f, respectively; P40.07 for all genes) biopsies, with the exception of increased expression of mucin 13 in the ileum of HIV-2-infected individuals (Po0.001).
Overall, sigmoid and ileum IL-22 production appear to be unaffected in HIV-2-infected individuals, a situation reflected by their maintained expression of markers of IL-22-dependent mucosal homeostasis.
Preserved tight junctions in HIV-2 infection
We hypothesized that maintained mucosal T-cell homeostasis might result from an intact epithelial barrier in the context of chronic HIV-2 infection. To test this possibility, we quantified the levels of ZO-1 protein, an important tight junction component, by immunofluorescence in different gut epithelial regions. We found similar ZO-1 expression in both the villi and upper epithelium of ileum (Figure 6a , P ¼ 0.14), as well as the upper epithelium and crypts in the colon (Figure 6b , P ¼ 0.97), in both cohorts. Of note, ZO-1 protein levels did not correlate with any of the above evaluated parameters, including IL-22 and the expression levels of IL-22-inducible genes.
Furthermore, we investigated the direct impact of HIV-2 on tight junction integrity, using an in vitro gut epithelial cell line model, with ZO-1 protein expression assessed by immunofluorescence as a read-out. 31 Both HIV-2 lab-adapted and primary isolates, utilizing either CXCR4 or CCR5 co-receptors, showed a reduced capacity to disrupt the ZO-1 network as illustrated in Figure 6c , as compared to HIV-1 IIIB , used here as a positive control. 31 Overall, these data suggest that gut mucosal integrity, at the level of epithelial tight junctions, is maintained during chronic HIV-2 infection, likely as a result of the reduced ability of HIV-2 to directly perturb the tight junction structure.
Increased mucosal expression levels of GM-CSF and chemokines linked to T-cell recruitment in HIV-2 infection
Finally, we asked whether the lack of tight junction disruption was effectively linked to preservation of the mucosal microenvironment despite HIV-2 replication. With this in mind, we 
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We found a relatively preserved structure of both ileum and sigmoid mucosa in HIV-2-infected individuals, as illustrated in Figure 7a and b, respectively. A blinded assessment by a trained pathologist revealed no significant difference in cellular infiltrate, as well absence of epithelial erosions and follicular structures within both ileum and sigmoid lamina propria (neutrophils, lymphocytes, and eosinophils), resulting in a comparable inflammatory score to seronegatives (sigmoid: 1.0 (1.0-2.0, n ¼ 13) vs. 1.0 (1.0-1.5, n ¼ 15), P ¼ 0.50; and ileum 1.0 (1.0-1.0, n ¼ 9) vs. 1.0 (1.0-1.0, n ¼ 11), P ¼ 0.22; in HIV-2-infected and seronegative individuals, respectively). Additionally, we found no evidence of increased collagen deposition in either ileum or sigmoid biopsies (Figure 7a and b, respectively), except in two untreated HIV-2-infected patients where there was increased collagen deposition in the ileum in the absence of detectable Gag protein or CD4 þ cell depletion (1,431 and 223 cells per mm 2 ). In agreement, both cohorts featured comparable gene expression levels of cytokines and other molecules known to be involved in the differentiation and/or survival of Th17, Th22, and Treg CD4 subsets, namely IL-6, IL-23, TGFb, and IDO1 (Figure 7a and b; P40 .55 for all genes). Of note, sigmoid biopsies from HIV-2-infected individuals featured lower levels of AHR (Figure 7b , P ¼ 0.004), a receptor relevant for the survival, proliferation, and function of both ILC3 and Th22. 32, 33 The relative amounts of the key anti-and pro-inflammatory cytokines, IL-10 and IL-1b were similar in both cohorts (Figure 7a and b; P40.76 for both). Moreover, in spite of the evidence of local HIV-2 replication, there was no increase in the transcriptional levels of MxA (Figure 7a for ileum and Figure 7b for sigmoid), a type I interferon inducible gene. 26 In this context, it is worth noting that GM-CSF expression was increased in the sigmoid of HIV-2-infected individuals (Figure 7b , P ¼ 0.04).
We also quantified the expression of two chemokines implicated in the recruitment of T-cells to the gut mucosa: CCL20, whose receptor, CCR6, is expressed by Th17 cells, 34 and CCL28, whose receptor, CCR10, is expressed on Th22 cells. 35 Importantly, we found a significant increase in CCL20 and CCL28 expression in sigmoid biopsies of HIV-2-infected individuals (Figure 7c , P ¼ 0.007 and P ¼ 0.001, respectively), suggesting that increased cell recruitment may play a role in maintaining CD4 T-cells in the sigmoid lamina propria of these individuals. Moreover, there was a direct correlation between the levels of GM-CSF and both CCL20 and CCL28 (Figure 7c) , suggesting that GM-CSF may help orchestrate this chemokine response. Of note, although we did not find increased gene expression levels of these chemokines in the ileum (CCL20: 1,749 (1,054-3,344) vs. 1,954 (1,382-19,014), P ¼ 0.38; CCL28: 1,491 (1,106-2,234) vs. 2,078 (1,332-5,871), P ¼ 0.15; arbitrary units, 11 HIV-2 vs. 10 seronegative individuals), the correlations between GM-CSF and CCL20 (r ¼ 0.5, P ¼ 0.01) and CCL28 (r ¼ 0.66, Po0.001) were maintained.
In conclusion, HIV-2-infected individuals featured a normal gut mucosal structure without evidence of local inflammation, paralleled by increased gene expression levels in sigmoid biopsies of GM-CSF and chemokines involved in CD4 T-cell recruitment, which likely help maintain the CD4 T-cell compartment and overall gut mucosal homeostasis. Our data led us to hypothesize that this local response, able to counteract any potential CD4 depletion induced by ongoing viral replication, may result from the absence of disruption of epithelial tight junctions and the consequent preservation of epithelial integrity in the context of HIV-2 infection.
DISCUSSION
This first study of chronic HIV-2-infected individuals' gut mucosa provides evidence for: (a) viral replication in the ileum and sigmoid, despite the undetectable viremia observed in all patients; (b) lack of CD4 T-cell depletion and maintained Th17 and Th22 compartments in the absence of increased FOXP3 þ Tregs; (c) preserved ILC3 cells, and innate production of IL-22 and IL-17; (d) normal mucosal structure and epithelial integrity; (e) preserved tight junctions in vivo and in an in vitro model of HIV-2 infection; and (f) increase in GM-CSF production in direct association with increased levels of chemokines involved in Th17 and Th22 recruitment, CCL20 and CCL28, respectively.
Our data support a model in which the maintenance of epithelial tight junctions and overall mucosal integrity, despite local HIV replication, protects mucosa from overwhelming microbial stimuli, and, thus, allows the establishment of repair mechanisms and mucosal responses to counteract CD4 T-cell depletion by promoting mucosal T-cell recruitment.
Our finding of ongoing HIV-2 replication in the gut mucosa despite undetectable levels of plasma viral load supports a compartmentalization of HIV-2 replication in the gut-associated lymphoid tissue. The mechanisms underlying the tissue control of HIV-2 viral replication, yet to be deciphered, can provide valuable information for understanding the control of Figure 4 Preserved distribution of cytokine production by mucosal CD4 T-cell subsets in HIV-2-infected individuals. The distribution of IL-17, IL-22, and IFNg production within sigmoid CD4 T-cells was analyzed using SPICE software and no differences were found using partial permutation test. IFN, interferon; IL, interleukin.
HIV replication and reservoirs in HIV-1-infected individuals under ART. We and others have shown that the levels of cellassociated proviral DNA in PBMC are comparable in HIV-1 and HIV-2 infections, 21, 23 supporting an equal ability of the two viruses to disseminate and persist. CCR5, expressed by the majority of mucosal CD4 T-cells, has been suggested to be the main in vivo co-receptor for HIV-2, 36 which is further supported by our data revealing the preferential targeting of the gut mucosa. In all five patients with undetectable proviral DNA in PBMC, there were detectable levels of proviral DNA in the gut (in three both in ileum and colon, in two only in sigmoid or ileum). In the future, it will be relevant to compare HIV-2 phylogenic diversity in the blood and gut. Moreover, it will be relevant to evaluate the contribution of our finding of local expansion of IFNg-producing CD8 T-cells to the gut containment of HIV-2 replication. Notably, we found no evidence of mucosal upregulation of type I Interferon, which is in agreement with our previous data generated using blood samples from a different cohort of HIV-2 infected individuals. 26 Massive mucosal CD4 T-cell depletion is known to occur very early during acute HIV-1 infection. 9 In this respect, there are no reports of HIV-2 acute infections, raising the possibility that the kinetics of viral dissemination may differ for the two viruses, and that HIV-2 plasma viral load may never reach the levels observed in HIV-1. 21, 37 Therefore, it is plausible that a slower rate of viral dissemination may facilitate the adequate mounting of mucosal responses enabling control of local viral replication. Moreover, tissue repair mechanisms are likely to change with age and to be impaired in infancy. This might explain our previous finding of mucosal CD4 T-cell depletion in an adolescent with HIV-2 infection acquired perinatally, 38 when microbial colonization of the gut is ongoing and the mechanisms underlying gut homeostasis and repair are still immature. 39 Tight junction conservation during HIV-2 infection is likely to be a key factor. In HIV-1 and SIV models, loss of tight junction integrity, via direct or indirect viral effects, is linked to overall mucosal disruption, 31 increased levels of microbial translocation, and consequent systemic immune activation. 8 The detailed mechanisms by which HIV-1 proteins are able to disrupt tight junctions remain unclear. 40 We showed here that HIV-2 is limited in its ability to directly impact tight junctions, providing a new model to investigate mechanisms of HIV disruption of the epithelial barrier. This has the potential to identify both new therapeutic and preventive targets, the latter to be combined with microbicides to protect the genital tract. In fact, it is plausible to speculate that the inability of HIV-2 to disrupt the epithelial barrier may, in addition to the low viremia, contribute to its low levels of sexual transmission. 37 Tight junction loss in HIV-1 infection is also a consequence of high local production of pro-inflammatory cytokines, such as IL-1 and IL-6. 41 We did not find an increase in their expression levels in HIV-2 infection. It is likely that the absence of disruption of epithelial lining limits the amount of microbial products able to reach the lamina propria and, thus, prevents 50 mm) ; graphs show mRNA levels of molecules involved in mucosal homeostasis in total RNA extracted from ileum (a) and sigmoid (b) biopsies from both cohorts; the total number of samples tested and those with levels above the detection threshold of the respective gene are shown below the graphs. (c) CCL20 and CCL28 mRNA levels in total RNA extracted from sigmoid biopsies of HIV-2-infected and seronegative individuals (left hand graph); and association between gene expression levels of CCL28 and GM-CSF (middle graph) and CCL20 and GM-CSF (right hand graph) in sigmoid biopsies from both cohorts. mRNA levels are expressed in relative units and normalized to the mean CT levels of GAPDH and r18S. Bars represent median values and interquartile range. Two-group comparisons were made using the Mann-Whitney U-test; Spearman correlation was used to calculate r coefficient and statistical significance; P-values o0.05 are shown. H&E, hematoxylin and eosin.
the local inflammatory responses that promote the vicious cycle that perpetuates tight junction loss in HIV-1 and SIV infections. On the other hand, it may allow the mounting of local responses mediated by IL-22 that further promote epithelial integrity.
Epithelial repair during inflammatory processes relies on multiple pathways. 2 In this regard, the preservation of ILC3 in HIV-2 infection is expected to play a fundamental role, not only due to their production of IL-22 but also because they control pro-inflammatory responses by CD4 T-cells. 42 Depletion of ILC3 during acute HIV-1 infection occurs both in the gut and peripheral blood, with the degree of depletion directly correlating with loss of barrier function. 15 Additionally, we have previously reported preserved mucosal homeostasis in treated HIV-1 individuals with persistent CD4 T-cell depletion and linked this finding to a preserved ILC3 compartment. 17 Importantly, in other disease settings such as chronic inflammatory bowel disease, ILC3 depletion was also found to contribute to epithelial disruption. 43 Unexpectedly, HIV-2-infected individuals featured reduced transcriptional levels of AHR, a key regulator of IL-22 production. The possible mechanisms underlying this finding, such as microbiome imbalances, deserve further exploration. Of note, although type I interferon has been shown to negatively regulate AHR expression, 44 this does not appear to be the case here, given the lack of increased in MxA expression, an interferon inducible gene.
Of note, both CD4 T-cell numbers and quality were preserved in the gut mucosa of HIV-2-infected individuals. CD4 T-cell depletion in HIV-1 infection has been attributed to multiple processes, including direct viral-induced cytopathicity and indirect mechanisms, such as alterations in T-cell traffic. 45 In fact, the levels of mucosal homing molecules in circulating CD4 T-cells, such as b7 integrin, directly correlates with gut CD4 T-cell frequency both in humans and non-human primates. 46 Our finding of increased levels of the chemokines CCL20 and CCL28, responsible for Th17 and Th22 recruitment, respectively, further support that cell recruitment plays an important role in mucosal T-cell homeostasis. Notably, we showed that this response directly correlated with increased mucosal production of GM-CSF. This cytokine is produced by several cell types, including ILC3 and is involved in maintaining a tolerogenic environment. 47 Interestingly, in recent murine studies, GM-CSF was shown to be relevant in an inflammatory context by increasing T-cell homing to the gut. 47, 48 This supports our proposed model in which GM-CSF orchestrates an adequate mucosal response able to counteract chronic viral replication that helps maintain gut homeostasis.
Overall, we revealed for the first time that persistent viral replication occurs in the gut of chronic HIV-2-infected individuals and is associated with a local immune response able to preserve CD4 T-cells and epithelial integrity, likely contributing to the more benign course of HIV-2 disease. Importantly, our data add significantly to the understanding of mucosal CD4 T-cell preservation in the presence of chronic inflammatory stimuli, with general implications for designing new therapies aimed at restoring gut mucosal homeostasis. (Table 1) were studied and compared with a previously described control cohort. 17 All individuals gave written informed consent for blood and gut biopsy collection. The study was conducted with approval of the Ethical Boards of the Faculty of Medicine of University of Lisbon, and Centro Hospitalar Lisboa Norte, Hospital São Bernardo, and Hospital Fernando da Fonseca, Portugal.
Cell isolation. Biopsies were collected from macroscopically normal mucosa, and immediately processed, as described. 17 Briefly, 7-10 sigmoid biopsies/individual were digested, mechanically macerated, lymphocytes separated by Percoll gradient (Sigma-Aldrich, GE Healthcare, Saint Louis, MO, USA), and rested for 16 h at 37 1C in complete medium prior to analysis. Blood was collected in parallel and PBMC isolated by Ficoll-Hypaque (Sigma-Aldrich) gradient centrifugation.
Flow cytometry. Cells were surface and intracellularly stained (Foxp3 Staining Buffer Set, EBioscience, San Diego, CA, USA), as described, 49 and acquired on a LSRFortessa flow cytometer (BD Biosciences, San Jose, CA, USA). Whole-blood staining was used to assess circulating lymphocyte populations and their expression of activation markers, as described. 26 Cytokine production was quantified following 4-h stimulation with phorbol myristate acetate, plus ionomycin, in the presence of Brefeldin A (Sigma-Aldrich), using unstimulated cells to define cytokine cut-offs. 17 Analysis of cytokine production was performed within ILC3 defined using ckit, NKp44, CD45, and Lin (CD3/CD14/CD16/CD19/CD123) or CD3, as well as within T-cell subsets defined using CD3, CD4, CD8, and FOXP3. The following antibodies against human (clone in brackets) were used: NKp44 (243415), CCR7 (150503) from R&D (Minnneapolis, MN, USA); CD3 (UCHT1), CD4 (RPA-T4), CD11c (B-Ly6), CD25 (M-A251), CD45 (HI30), CD45RO (UCHL1), CD56 (My31) from BD Bioscience; CD123 (6H6), IFNg (4S.B3) from Biolegend (San Diego, CA, USA); CD3 (OKT3), CD4 (RPA-T4), CD8 (RPA-T8), CD14 (61D3), CD16 (eBioCB16), CD19 (HIB19), Cd38 (HB7), CD45 (2D1), CD45RO (UCHL1), Cd117 (104D2), FOXP3 (L243), IL-17 (eBIO54DEC17), IL-22 (22URTI) from EBioscience. Eight-color flow cytometry analysis was performed with FlowJo (Tree Star, Ashland, OR, USA), after exclusion of dead cells (Live/Dead-LD, Thermo Fisher Scientific, Carlsbad, CA, USA) and doublets, within gated populations containing X150 events, with expression of molecules normalized to unstained and/or unstimulated samples.
Immunohistochemistry staining. One sigmoid and one ileum biopsy/ individual were embedded in paraffin after preservation in 4% formaldehyde. About 3 mm sections were stained as previously described, 17 and revealed with Dako EnVision Detection Systems Peroxidase/DAB, Rabbit/Mouse kit (Agilent Technologies, Santa Clara, CA, USA), using the following primary antibodies (clone in brackets) against CD4 (4B12), CD8 (1A5), and FOXP3 (236/E7) from Leica Biosystems (Wetzlar, Germany); IL-17 polyclonal from Santa Cruz Biotechnology (Dallas, TX, USA); and p27 (ARP 396/397) from AIDS Research and Reference Reagent Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, from Dr P Szawlowski, followed by HRP-Labeled Polymer from DAKO/Agilent Technologies. Cells with lymphocyte morphology were counted in 10 images ( Â 400) acquired with a Leica DM2500 brightfield microscope, and lamina propria area assessed using ImageJ 1.47i (https://imagej.nih.gov/ij/index.html), in blinded samples by two researchers. H&E, Masson's trichrome, and periodic acid Shiff-Alcien Blue staining were performed concurrently, and blindly evaluated by a trained pathologist. Samples were scored according to inflammatory alterations, type of infiltrate, presence or absence of fibrosis, and number of mitotic figures at the crypt base using an arbitrary scale ranging from 0 to 3.
Immunofluorescence staining. One sigmoid and one ileum biopsy/ individual were frozen in optimal cutting temperature compound (VWR, Radnor, PA, USA) and stained as described. 17 About 3 mm tissue sections were sequentially stained with antibodies after protein blocking, and 4 0 ,6-diamidino-2-phenylindole (DAPI) was used for nuclear counterstaining. Primary antibodies used were rabbit antiRORgt (Abcam, Cambridge, UK), goat anti-IL22 (Santa Cruz Biotechnology), rat anti-CD3 (clone CD3-12 from Acris, Herford, Germany), and mouse anti-ZO-1(clone 1/ZO-1 from BD Biosciences). The respective secondary antibodies were from Molecular Probes, Thermo Fisher Scientific (Waltham, MA). Images were acquired with Zeiss LSM710 confocal point-scanning microscope (Carl Zeiss, Oberkochen, Germany) using a EC Plan-Neofluar Â 40/1.30 objective. Surface area was measured with ImageJ 1.47i, and positive cells counted using in-house software, written in MATLAB (Mathworks, Natick, MA, USA), allowing automatic generation of individual report images for cell-counting verification. 17 Regarding ZO-1 expression, the total amount was measured as a percentage of the epithelium area by Fiji, using thresholds setting for two channels: DAPI in blue and ZO-1 in green.
RNA/DNA extraction and analysis. One sigmoid and one ileum biopsy were stored in RLT buffer (Qiagen, Valencia, CA, USA) immediately post collection. RNA and DNA were extracted using Allprep RNA/DNA mini kit (Qiagen). cDNA was synthesized from 250 ng of RNA (SuperScript III), and used to quantify the expression levels of MxA using KiCqStart primers and Power SYBR Green master mix, as well as IL22, IL17A, IL22RA1, IL-23, IL23R, IL25, TGFB1, IL1B, IL-6, IL-10, CCL20, CCL28, GM-CSF, MUC1, MUC13, S100A9, REG3G, DEFB4A, AHR, and IDO1 after pre-amplification with TaqMan Preamp Master Mix, using Applied Biosystems TaqMan gene expression assays and Applied Biosystems 7500 Fast or ViiA7 RealTime PCR Systems (all from Thermo Fisher Scientific except MxA from Sigma-Aldrich). Results are expressed using the DCt method (normalized to the average cycle threshold (Ct) values of GAPDH and r18S). Cell-associated HIV-2 DNA was quantified by a nested qPCR using the following primers and probes: HIV-2 gag out-forward 0 -CTCTCTAGCAGAGAACAGT-3 0 -MGB. Standard curves were generated from serial dilutions of a plasmid containing both amplicons. 22 Cell-associated HIV-2 DNA was quantified in 50 ng of total DNA purified from PBMCs or from digested gut biopsies. The first step of the PCR was carried out in a 50 ml reaction mix containing the ''outer'' primers, dNTPs, MgCl2, Taq DNA Polymerase (GoTaq Flexi, Promega, Madison, WI), buffer, and 5 ml of DNA or of serial dilutions of the plasmid. The amplification reaction was performed using a Bio-Rad T100 Thermal Cycler (Hercules, CA), as follows: 2 min denaturation at 95 1C, 20 cycles of 95 1C for 30 s, 60 1C for 30 s, and 72 1C for 2 min, 5 min extension at 72 1C. The reaction mix for the second step was composed of 5 ml of PCR product diluted 1:50 (including standard curves), TaqMan gene expression master mix and the ''in'' primers and probes. Amplification was performed using a 7500 Fast Real-Time PCR system. Plasma HIV-2 viral load was quantified by RT-PCR using a previously described assay, 37 with a detection cut-off of 40 RNA copies per ml.
Colon cell line cultures with HIV. Human colon-derived crypt-like T84 epithelial cell line (ATCC catalogue CCL-248) was maintained according to previously published protocols.
31 T84 cells were seeded in a 4-well-chamber slide (Lab-Tek II RS glass, Nunc, Thermo Fisher Scientific) and grown for 3-4 days until reaching near confluence, as determined by light microscopy. Cells were then cultured for an additional 24 h with medium alone or with 10,000 TCID50 of labadapted viruses HIV-2 ROD or HIV-1 IIIB (both CXCR4-tropic); or HIV-2 primary isolates HIV-2 60,415 K (CCR5-tropic) or HIV-2 20 .04 (CXCR4-tropic), obtained as previously described. 22 Immunofluorescence staining for ZO-1 was performed and standardized 30-slice range Z-Stack acquired on confocal LSM710. Representative images are maximum intensity projections of the z-stacks using ImageJ 1.47i.
Statistical analysis. Results are expressed as medians and interquartile range. Two-group comparisons were made using MannWhitney U-test or Wilcoxon Signed Rank test with Graph Prism 5.0 (GraphPad Software, San Diego, CA, USA). Non-adjusted regression analysis or Spearman correlation was used to identify associations between several parameters. Distribution of cytokine production by CD4 þ T-cells was analysed with SPICE version 5.1 (downloaded from http://exon.niaid.nih.gov) using Wilcoxon Signed Rank test and partial permutation test. 50 P-values below 0.05 were considered significant.
